Hepatitis

Treatment failure in chronic hepatitis B

The failure of antiviral therapy for chronic hepatitis B can involve both virological breakthrough and genotypic resistance. A study of the failure of nucleoside analogue therapy suggests that drug-resistant mutants are not solely responsible for treatment failure. Suboptimal treatment adherence might also have an important role.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Soriano, V., Perelson, A. S. & Zoulim, F. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62, 1–4 (2008).

  2. 2

    Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750–1758 (2004).

  3. 3

    Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593–1608 (2009).

  4. 4

    Hongthanakorn, C. et al. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogs in clinical practice. Hepatology doi:10.1002/hep.2 4318.

  5. 5

    Snow-Lampart, A. et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53, 763–773 (2011).

  6. 6

    Chang, T. T. et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 51, 422–430 (2010).

  7. 7

    Osterberg, L. & Blaschke, T. Adherence to medication. N. Engl. J. Med. 353, 487–497 (2005).

  8. 8

    Chotiyaputta, W., Peterson, C., Ditah, F. A., Goodwin, D. & Lok, A. S. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis. B. J. Hepatol. 54, 12–18 (2011).

  9. 9

    Patterson, S. J. et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis. B. Gut 60, 247–254 (2011).

  10. 10

    Lee, P. K., Kieffer, T. L., Siliciano, R. F. & Nettles, R. E. HIV-1 viral load blips are of limited clinical significance. J. Antimicrob. Chemother. 57, 803–805 (2006).

Download references

Author information

Correspondence to Fabien Zoulim.

Ethics declarations

Competing interests

F. Zoulim has been a Consultant for Bristol–Myers Squibb, Gilead and Novartis. He has also been on the Speakers' Bureau for Bristol–Myers Squibb and Gilead and has received grant/research support from Gilead and Roche.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zoulim, F. Treatment failure in chronic hepatitis B. Nat Rev Gastroenterol Hepatol 8, 366–367 (2011). https://doi.org/10.1038/nrgastro.2011.104

Download citation

Further reading